You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

To understand the potential cost savings the Ellipta portfolio could offer your local health economy.

Email us now

This service is available
Monday – Friday: 9am - 5pm
(excluding bank holidays).

Using data tailored to your locality, the HOC: on-Demand service can:

Answer your query over the phone

Set up a digital meeting to support you using a virtual presentation

Schedule a face-to-face appointment with your local HOC

Before contacting us, please note:

  • This service is for healthcare professionals and other relevant decision makers resident in the UK only.
  • You are required to provide information for us to validate that you are a healthcare professional or other relevant decision maker. Please note that there may be a delay in answering your query if the required information is missing.
  • By using this service, you are agreeing to being contacted by GSK via email or telephone to discuss the financial impact of using GSK medicines in your health economy. Your email address will not be retained for any other purpose.
  • This service should not be used to report adverse events (please report any adverse event here).
  • By using this service you agree to have read and understood the GSK Privacy Policy and Terms and Conditions.

Please note: We will aim to respond to you within 24 hours, however this may be longer during busy periods.

Browse through our case studies about respiratory medicines optimisation and find out how other HCPs have utilised the Ellipta portfolio

Case study 1

Simplifying and streamlining COPD treatment: Chronic obstructive pulmonary disease strategy.

Download PDF 465KB

Case study 2

The role of bronchodilators in the treatment of COPD:
An interview with Dr. Owen Johnson.

Download PDF 224KB

Case study 3

Medicines optimisation in respiratory – a pharmacist’s perspective. An interview with Bernadette Hutton.

Download PDF 2.1MB

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Anoro, Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies